Canopy Growth Corporation

NASDAQ:CGC

Drug Manufacturers - Specialty & Generic

Healthcare
$0.50 +1.07%

+$0.01 today

Market cap
$212.31M
Beta
0.78
P/E (TTM)
-1.8
EPS (TTM)
-$0.76
52W Low $0.84High $2.38

Volume 3.44M

Average 9.97M

CGC EBITDA Margin

EBITDA as a percentage of revenue.

Canopy Growth CorporationNASDAQ: CGC

EBITDA Margin · Q4 FY2025 · quarter ended Mar 2026

EBITDA Margin widens to -192.3%

EBITDA Margin was -192.3% in Q4 FY2025, up 106.5 pp from a year earlier. On a trailing-twelve-month basis it was -65.7%, up 112.4 pp year over year. Over 3 fiscal years it widened by 874.7 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 5 analysts of 24.2% for the fiscal year ending Mar 2027, up from 10.5% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-192.3%-130.6 pp QoQ
Last fiscal yearMar 2026
10.5%+188.7 pp YoY
LTMMar 2026
-65.7%+112.4 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+106.5 pp+39.1 pp-67.4 pp
1 year+188.7 pp+13.6 pp-175.1 pp
3 years+874.7 pp+16.0 pp-858.8 pp
5 years+15.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
10.5%
Year-over-year change
+188.7pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How CGC compares with its peers on the latest reported figures

  • CGC's LTM Mar 2026 EBITDA Margin of -65.7% is the 6th highest of the 9 companies compared; the peer median is -12.3%.
  • Its year-over-year change of +112.4 pp is the 3rd highest of 8, against a peer median of +18.3 pp.
  • Over three fiscal years its change of +874.7 pp compares with a peer median of -28.3 pp.
CGC Competitors Peer median
EBITDA Margin for CGC and competitors
Company Period LTM level YoY 3-year change
IRWDIronwood Pharmaceuticals, Inc.LTM Mar 202657.3% +32.9 pp-28.3 pp
DHDefinitive Healthcare Corp.LTM Mar 20264.9% +295.3 pp-78.9 pp
ACBAurora Cannabis Inc.LTM Mar 20263.4% -11.6 pp+14.0 pp
LFCRLifecore Biomedical, Inc.LTM Mar 2026-0.8% —-18.4 pp
TKNOAlpha Teknova, Inc.LTM Mar 2026-23.8% +18.3 pp+37.0 pp
CGCCanopy Growth CorporationLTM Mar 2026-65.7% +112.4 pp+874.7 pp
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-843.9% -542.0 pp-540.2 pp
BIOABioAge Labs, Inc.LTM Mar 2026-864.8% +3922.9 pp—
LYELLyell Immunopharma, Inc.LTM Mar 2026-770932.3% -482924.6 pp-730107.8 pp
CABACabaletta Bio, Inc.FY2025— ——
Peer median (excluding CGC) -12.3%+18.3 pp-28.3 pp

Competitors are the stored peer set for CGC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Mar 2022
FY2022
Mar 2023
FY2023
Mar 2024
FY2024
Mar 2025
FY2025
Mar 2026
Revenue475.7M333.25M297.15M269M483.67M
Cost of Revenue663.11M396.78M216.26M189.48M386.51M
Gross Profit(187.41M)(63.53M)80.88M79.51M97.16M
Gross Margin-39.4%-19.1%27.2%29.6%20.1%
Research & Development32.26M21.72M4.61M1.91M0
Selling, General & Admin361.1M297.98M180.59M121.71M223.11M
Operating Expenses831.39M2.57B309.6M196.65M322.6M
Depreciation & Amortization110.94M80.03M53.18M43.12M50.86M
EBITDA(52.98M)(2.88B)(312.83M)(479.31M)50.86M
EBITDA Margin-11.1%-864.2%-105.3%-178.2%10.5%
Operating Income(1.02B)(2.63B)(228.71M)(117.14M)(161.66M)
Operating Margin-214.2%-789.3%-77.0%-43.5%-33.4%
Interest Income6.6M24.28M16.24M8.82M10M
Interest Expense103.94M126.16M105.35M74.57M38.19M
Other Income / Expenses750.94M(455.64M)(242.64M)(479.85M)(101.23M)
Income Before Tax(267.86M)(3.09B)(471.36M)(597M)(262.89M)
Pre-Tax Margin-56.3%-926.1%-158.6%-221.9%-54.4%
Income Tax Expense(8.95M)(5.73M)12.33M7.14M23K
Net Income(310.04M)(3.28B)(657.27M)(598.12M)(366.64M)
Net Margin-65.2%-983.7%-221.2%-222.4%-75.8%
EPS (Basic)(7.70)(70.70)(6.47)(5.53)(0.88)
EPS (Diluted)(7.70)(70.70)(8.79)(5.53)(0.88)
Weighted Avg Shares39.13M46.37M101.63M107.55M2.98B
Weighted Avg Shares (Diluted)39.13M46.37M74.79M107.55M2.98B

Canopy Growth Corporation

NASDAQ:CGC

Intrinsic Alpha fair value

Locked

Current Price

$0.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.